Both ADM‐enhancing therapies aimed at improving endothelial barrier function and DPP3‐blocking therapies aimed at restoring systemic angiotensin responses have been shown to improve outcome in various preclinical sepsis models. This evidence concerns the gene DPP3 and Sepsis.